← Leaderboards
Tayebeh Pourmotabbed
University Of Tennessee Health Sci Ctr
$1,895,511
Attributed
$2,258,511
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $308K · FY2005–22$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,258,511 · 4
By mechanism
R01$1,532,511 · 2
R21$418,000 · 1
R03$308,000 · 1
Top collaborators
- Anton J. Reiner2 shared
- Mohammad Moshahid Khan1 shared
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Anton J. Reiner$10,082,754
- Miranda Alvina Marie Hallett$41,976
- Susan R Rose$61,208
- Mohammad Moshahid Khan$729,500
- Chunxiang Zhang$4,904,212
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseIn VitroBrainOligonucleotidesIn VivoSafetyDesignProteinsResearch PersonnelToxic EffectInjection Of Therapeutic AgentNeuraxisBrain NeoplasmsCatalytic DnaPreventBaseMessenger RnaAdverse EffectsAntisense OligonucleotidesAnimalsAnimal ModelCell StromaDiagnosisBinding
Grant awards (10)
Development of a novel gene therapy for the treatment of tauopathy$308,000
R03 · FY2022 · AG
Development of DNAzyme Gene Therapy for Huntington's Disease$228,000
R21 · FY2017 · NS
Development of DNAzyme Gene Therapy for Huntington's Disease$190,000
R21 · FY2016 · NS
Targeting Glioma by Anti-MMPs-2 and -9 DNAzymes$246,068
R01 · FY2009 · CA · contact PI
Targeting Glioma by Anti-MMPs-2 and -9 DNAzymes$246,068
R01 · FY2008 · CA · contact PI
Targeting Glioma by Anti-MMPs-2 and -9 DNAzymes$246,068
R01 · FY2007 · CA · contact PI
Targeting Glioma by Anti-MMPs-2 and -9 DNAzymes$253,417
R01 · FY2006 · CA · contact PI
Targeting Glioma by Anti-MMPs-2 and -9 DNAzymes$257,698
R01 · FY2005 · CA
TYPE V COLLAGENASE IN RHEUMATOID ARTHRITIS$143,667
R01 · FY2001 · AR
TYPE V COLLAGENASE IN RHEUMATOID ARTHRITIS$139,525
R01 · FY2000 · AR